Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

In vivo gene editing with YOLT-201 for transthyretin amyloid cardiomyopathy – an open-label, first-in-human clinical trial

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive and life-threatening disease driven by continuous hepatic production of misfolded transthyretin. Existing therapies slow progression but require chronic administration. YOLT-201 is an in vivo CRISPR-Cas9 gene-editing therapy delivered by lipid nanopa...

X. Guo, H. Yan, J.-Y. Liao et al. · 0 citations
Open access Aug 2026

Complement C3 inhibitory peptide AMY-101 ameliorates brain injury in a mouse model of NMOSD

It is demonstrated that complement C3 inhibition with AMY-101 effectively ameliorates key pathological features of NMOSD in experimental models, supporting its potential as a therapeutic strategy and providing a rationale for further preclinical and clinical investigation.

Wenli Zhu, Fang-Ping He, Fan-Xia Meng et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.